InsiderTrades

Form 4 for DNTH Dianthus Therapeutics, Inc. /DE/

Accepted 2025-12-05 00:00:00 ET · period of report 2025-12-04 · accession 0001992324-25-000005 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DT 2025-12-05 2025-12-04 DNTH Savitz Ryan CFO, CBO S - Sale+OE $45.18 -20.0K 0 -100% -$903.6K
DT 2025-12-05 2025-12-04 DNTH Savitz Ryan CFO, CBO M - OptEx $8.44 +20.0K 20.0K New +$168.8K
DT 2025-12-05 2025-12-04 DNTH Savitz Ryan CFO, CBO M - OptEx $0.00 +20.0K 84.8K +31% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-12-04 S D 20,000 $45.18 0 D — — (F2) The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
2 Common Common Stock 2025-12-04 M A 20,000 $8.44 20,000 D — —
3 Derivative Stock Option (Right to Buy) 2025-12-04 M A 20,000 $0.00 84,766 D $8.44 · — to 2032-06-06 20,000 Common Stock (F3) The shares of common stock underlying this stock option award vested as to 25% of the shares on June 2, 2023, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.